Where Does Jaguar Health Inc. (JAGX) Rank When It Comes To Price-To-Earnings Ratio?

0
10
KOSK
KOSK

Jaguar Health Inc. (NASDAQ:JAGX) finished Thursday with a subtraction of -$0.01 to close at $0.17, a downside of -7.82 percent. An average of 4,442,400 shares of common stock have been traded in the last five days. There was a fall of -$0.0654 in the past week, and it reached a new high 2 times over the past 12 months. The last 20 days have seen an average of 4,341,695 shares traded, while the 50-day average volume stands at 5,184,162.

JAGX stock has decreased by -31.59% in the last month. The company shares reached their 1-month lowest point of $0.1554 on 09/22/22. With the stock rallying to its 52-week high on 01/04/22, shares of the company touched a low of $0.18 and a high of $2.66 in 52 weeks. It has reached a new high 2 times so far this year and lost -84.01% or -$0.8737 in price. In spite of this, the price is down -93.75% from the 52-week high.


China Can't Stop US$0.25 Stock from Mining Ultra-Rare Metal

Here's one little-known company — trading undiscovered below 25-cents per share — that's advancing one of the largest and highest quality REE deposits in all of North America... and the Chinese can't do a damn thing about it! It's early stage... and that's excellent news for individual investors like you who have the foresight to act decisively on an emerging megatrend that's already being measured in the Tens of $Billions.

Simply click here and the name & trading symbol are yours.

Sponsored


Valuation Metrics

Jaguar Health Inc. (JAGX) stock’s beta is 1.67. Other valuation ratios to consider include the trailing price-to-sales (P/S) ratio at 2.53, the price-to-book (PB) ratio at 5.54.

Financial Health

The quick ratio of Jaguar Health Inc. for the three months ended March 30 was 0.70, and the current ratio was 1.00, indicating that the company is not able to meet its debt obligations. Further, the company has a long term debt to equity ratio of 8.67 and a total debt to equity ratio of 11.63 for the quarter ending March 30. Its gross profit as reported stood at $2.0 million compared to revenue of $4.33 million.

For investors, determining the potential profitability of the investment also depends on the performance of the company’s management. In the past 12 months, Jaguar Health Inc.’s return on assets was -100.10%.

Earnings Surprise

For the three-month period that ended March 30, Jaguar Health Inc. had $23.36 million in total debt. In the quarter under review, the net income was up than the previous quarter. The company posted a net income of -$9.37 million in the quarter, while revenues of -$17.99 million were shrunk -50.27%. The analyst consensus anticipated Jaguar Health Inc.’s latest quarter earnings to come in at -$0.17 per share, but it turned out to be -$0.4, a -135.30% surprise. For the quarter, EBITDA amounted to -$3.0 million. Shareholders own equity worth $120.04 million.

Technical Picture

From a technical analysis perspective, let’s take a brief look at Jaguar Health Inc. (JAGX) price momentum. RSI 9-day as of the close on 22 September was 18.81%, suggesting the stock is oversold, with historical volatility in this time frame at 87.63%.

As of today, JAGX’s price is $0.1880 -28.23% or -$0.0654 from its 5-day moving average. JAGX is currently trading -29.56% lower than its 20-day SMA and -62.85% lower than its 100-day SMA. However, the stock’s current price level is -49.59% below the SMA50 and -85.79% below the SMA200.

The stochastic %K and %D were 5.17% and 8.94%, respectively, and the average true range (ATR) was 0.0210. With the 14-day stochastic at 10.72% and the average true range at 0.0217, the RSI (14) stands at 24.26%. The stock has reached -0.0301 on the 9-day MACD Oscillator while the 14-day reading was at -0.0335.

Analyst Ratings

Cantor Fitzgerald launched coverage on Jaguar Health Inc. (NASDAQ: JAGX) in its analyst report released on July 07, 2021. The firm assigned the stock an Overweight rating. The consensus rating for Jaguar Health Inc. (JAGX) among analysts is Buy. According to current brokerage recommendations, 0 brokerage firms advise that investors sell JAGX, while 0 suggest investors hold. There are 0 analysts who rate the stock as underweight. The stock is rated overweight by 0 analysts, while 1 others rate it as a “buy”.

What is JAGX’s price target for the next 12 months?

Analysts predict a range of price targets between $5.00 and $5.00, with a median target of $5.00. Taking a look at these predictions, the average price target given by analysts for Jaguar Health Inc. (JAGX) stock is $5.00.

LEAVE A REPLY

Please enter your comment!
Please enter your name here